Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.
Article activity feed
-
-
SciScore for 10.1101/2022.01.26.22269885: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Eligible individuals from participating LTCFs provide written informed consent for study participation and consultees are sought for residents lacking capacity to consent.
IRB: VIVALDI has been granted research ethics approval by the South Central-Hampshire B Research Ethics Committee (ref:20/SC/0238).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis Formal sample size calculation was not undertaken. Table 2: Resources
Antibodies Sentences Resources Anti-nucleocapsid antibodies are used to identify immune responses stimulated by prior infection[16]. Anti-nucleocapsidsuggested: NoneTo model post-vaccination MSD assay anti-spike antibody … SciScore for 10.1101/2022.01.26.22269885: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Eligible individuals from participating LTCFs provide written informed consent for study participation and consultees are sought for residents lacking capacity to consent.
IRB: VIVALDI has been granted research ethics approval by the South Central-Hampshire B Research Ethics Committee (ref:20/SC/0238).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis Formal sample size calculation was not undertaken. Table 2: Resources
Antibodies Sentences Resources Anti-nucleocapsid antibodies are used to identify immune responses stimulated by prior infection[16]. Anti-nucleocapsidsuggested: NoneTo model post-vaccination MSD assay anti-spike antibody levels, individuals were categorised as either having ‘no evidence of prior infection’ or ‘evidence of prior infection’. anti-spikesuggested: NoneSoftware and Algorithms Sentences Resources The latter group included individuals with at least one record of an active infection defined by PCR or point-of-care lateral flow test (LFT) positivity or hospitalisation with COVID-19 prior to second vaccine dose, and those with presence of anti-nucleocapsid antibodies on either Abbott or MSD assay. Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title ISRCTN14447421 NA NA Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
-
